Aclaris Therapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Aclaris Therapeutics (NASDAQ:ACRS) reported Q4 earnings, beating estimates with an EPS of $-0.3 against an expected $-0.34. Revenue increased by $9.82 million from the previous year. Despite beating EPS estimates in the past, such performance has previously led to a 1.0% drop in share price the following day.
February 27, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aclaris Therapeutics reported better than expected Q4 earnings with an EPS of $-0.3 and a significant revenue increase from the previous year.
Despite Aclaris Therapeutics beating earnings estimates, historical data shows that such beats have previously led to a short-term drop in share price. Given this pattern, a similar outcome could be expected in the short term, although the significant revenue increase might mitigate some negative impact.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100